Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Efinaconazole

FDA-approved product (solution, topical), marketed as Efinaconazole, Jublia.

Registered studies
7
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Efinaconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Tinea
  • Tinea unguium

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Imidazole and triazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D01AC19; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

7registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Efinaconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Efinaconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the Toenails

    NCT07382427 · start 2026-03

    Registered record
    Registry ID
    NCT07382427
    Conditions
    Onychomycosis of Toenail
    Interventions
    2.4% Topical Terbinafine; 10% Topical Efinaconazole; Vehicle Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2028-02
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnychomycosis of Toenail
    Intervention2.4% Topical Terbinafine; 10% Topical Efinaconazole; Vehicle Control
    PhasePhase 2
    Registry statusNot yet recruiting

  • Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis

    NCT03280927 · start 2017-11-10

    Registered record
    Registry ID
    NCT03280927
    Conditions
    Mild to Moderate Onychomycosis Due to Dermatophyte
    Interventions
    Jublia®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-11-10
    Completion
    2020-01-22
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild to Moderate Onychomycosis Due to Dermatophyte
    InterventionJublia®
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients

    NCT03168841 · start 2017-06-06

    Registered record
    Registry ID
    NCT03168841
    Conditions
    Onychomycosis
    Interventions
    Efinaconazole Topical
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-06-06
    Completion
    2019-01-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnychomycosis
    InterventionEfinaconazole Topical
    PhasePhase 3
    Registry statusCompleted

  • Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis

    NCT02812771 · start 2016-08-04

    Registered record
    Registry ID
    NCT02812771
    Conditions
    Onychomycosis
    Interventions
    Efinaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-08-04
    Completion
    2019-01-14
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnychomycosis
    InterventionEfinaconazole
    PhasePhase 4
    Registry statusCompleted

  • Real-World Evaluation of the Effect of Jublia on Nail Polish

    NCT03022916 · start 2015-09

    Registered record
    Registry ID
    NCT03022916
    Conditions
    Evaluation of Jublia on Nail Polish With Healthy Toenails
    Interventions
    Nail Polish + Efinaconazole Solution; Nail polish; Base Coat + Nail Polish + Top Coat + Efinaconazole Solution; Nail Polish + Top Coat + Efinaconazole Solution
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-09
    Completion
    2017-12
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEvaluation of Jublia on Nail Polish With Healthy Toenails
    InterventionNail Polish + Efinaconazole Solution; Nail polish; Base Coat + Nail Polish + Top Coat + Efinaconazole Solution; Nail Polish + Top Coat + Efinaconazole Solution
    PhaseNot applicable
    Registry statusCompleted

  • Study Evaluating the Effect of Jublia on Dermatophytomas

    NCT03098615 · start 2015-09

    Registered record
    Registry ID
    NCT03098615
    Conditions
    Onychomycosis; Dermatophytosis
    Interventions
    Jublia (Efinaconazole 10% Topical Solution)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-09
    Completion
    2018-07
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnychomycosis; Dermatophytosis
    InterventionJublia (Efinaconazole 10% Topical Solution)
    PhasePhase 4
    Registry statusCompleted

  • Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish

    NCT03110029 · start 2015-09

    Registered record
    Registry ID
    NCT03110029
    Conditions
    Onychomycosis of Toenail
    Interventions
    Efinaconazole 10% Topical Application Solution [JUBLIA]; Application of Nail Polish
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-09
    Completion
    2018-07
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnychomycosis of Toenail
    InterventionEfinaconazole 10% Topical Application Solution [JUBLIA]; Application of Nail Polish
    PhasePhase 4
    Registry statusCompleted